Skip to main content
Premium Trial:

Request an Annual Quote

Molecular Mining Enters Drug Target Discovery Collaboration with Cytochroma

NEW YORK, May 1 - Molecular Mining is using its data mining software in a collaboration with Cytochroma, a Canadian company that uses genomic information to identify and develop drugs that target cytochrome p450 enzymes, the companies said Tuesday.

Under the arrangement, Molecular Mining is employing the software in a search for novel genes to serve as potential drug targets for Cytochroma. Molecular Mining has already identified hundreds of gene sequences that are homologous to cytochrome p450 sequences, Cytochroma said.

Cytochroma is paying an undisclosed fee to Molecular Mining, as well as "some sharing of the upside of things," in the event that gene-based drug targets yield marketable therapeutic candidates, said Robert Foldes, CEO of Cytochroma. The collaboration is open-ended, and will last for "as long as we want to explore genomes," Foldes added.

Cytochroma of Kingston, Ontario, decided to partner with Molecular Mining, because the company is located nearby, also in Kingston, and because its scientists were able to work with Cytochroma to develop custom algorithms based on Cytochroma's knowledge of p450 sequences, according to Foldes. The algorithms are based on a Hidden Markov model, Foldes said.

"Our collaboration with Molecular Mining has already yielded important insights into the complement of human genes that encode this family of enzymes," said Martin Petkovich, co-chief scientific officer of Cytochroma, in a statement. "What we have also gained from mining the human  genome is a means to tap into the genomes of other organisms of medical relevance including fungi, parasites, bacteria etc. The potential to identify new and valuable cytochrome P450 based drug targets is enormous."

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.